Bionify Bioscience (opc) Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bionify Bioscience (opc) Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $82.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bionify Bioscience (opc) Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $82.5K Trade | TransData Nexus

Bionify Bioscience (opc) Private Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $82.5K Total Trade · DGFT Verified

Bionify Bioscience (opc) Private Limited is an Indian pharmaceutical exporter with a total trade value of $82.5K across 2 products in 2 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Reagent ($77.6K), Biotin ($4.9K), .

Bionify Bioscience (opc) Private Limited — Export Portfolio & Destination Treemap

Bionify Bioscience (opc) Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bionify Bioscience (opc) Private Limited? — Company Overview & Market Position

Bionify Bioscience (opc) Private Limited is a healthcare enterprise based in Nagpur, Maharashtra, India. Established on May 25, 2022, the company operates as a Private One Person Company under the Corporate Identification Number (CIN) U51909MH2022OPC383348. The authorized and paid-up capital is ₹20,000 each. The registered office is located at Flat No 12 Block C Vandana Co-Op H Soc Canal Road, Nagpur, Maharashtra, 440010. The company is unlisted and is classified as a non-government company.

What Does Bionify Bioscience (opc) Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Reagent$77.6K 2Biotin$4.9K

Bionify Bioscience (opc) Private Limited Therapeutic Categories — 2 Specializations

Bionify Bioscience (opc) Private Limited operates across 2 therapeutic categories, with representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Product Portfolio — Top 2 by Export Value

Bionify Bioscience (opc) Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Reagent	Medical Devices & Diagnostics	$77.6K	41	0.6%	10
2	Biotin	Vitamins & Supplements	$4.9K	3	0.3%	7

Bionify Bioscience (opc) Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $82.5K. The top category is Medical Devices & Diagnostics (94.1% of portfolio), followed by Vitamins & Supplements (5.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Bionify Bioscience (opc) Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

As of the available data, Bionify Bioscience (opc) Private Limited does not have publicly disclosed manufacturing facilities. The company's operations are primarily focused on the wholesale trade and commission trade, excluding motor vehicles and motorcycles. There is no specific information regarding manufacturing plant locations, capacities, or specializations.

3Key Leadership

The company is led by Director Divya Ramprakash Khandelwal, who has been associated with Bionify Bioscience (opc) Private Limited since its incorporation on May 25, 2022. There is no publicly available information regarding other key executives such as the CEO, CFO, or additional directors.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bionify Bioscience (opc) Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bionify Bioscience (opc) Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a total export value of $83,000 USD across 44 shipments, with products spanning two therapeutic categories. The top five products exported are Reagent ($78,000, Rank #10, 0.6% market share) and Biotin ($5,000, Rank #7, 0.3% market share). The primary therapeutic categories are Medical Devices & Diagnostics (94.1%) and Vitamins & Supplements (5.9%). The company does not hold a market leader position in any category. The portfolio is highly concentrated, with the top five products accounting for 100% of the export value.

2Emerging Markets

There is no specific information available regarding Bionify Bioscience (opc) Private Limited's penetration into emerging markets such as Africa, Latin America, or Southeast Asia. The company's export data does not indicate any significant presence in these regions. Additionally, there is no information on WHO prequalification or other certifications that would enable access to these markets.

3Geographic Strategy

Bionify Bioscience (opc) Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding Bionify Bioscience (opc) Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's export data does not indicate any exports to the United States, suggesting limited or no engagement with the U.S. market.

2WHO & EU GMP

The available data does not provide information on whether Bionify Bioscience (opc) Private Limited holds WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's export activities do not appear to include shipments to regions requiring these certifications.

3CDSCO & Indian Regulatory

There is no specific information available regarding Bionify Bioscience (opc) Private Limited's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, or export No Objection Certificates (NOCs). The company's export data does not indicate any significant exports within India or to countries requiring such certifications.

Bionify Bioscience (opc) Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Bionify Bioscience (opc) Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's export data indicates a narrow product portfolio, which may limit its competitiveness in the broader market. Without information on specific competitors, market share comparisons, or head-to-head analyses, it is challenging to assess the company's position relative to its peers.

2Key Differentiators

The company's export data highlights a focus on specific products, such as Reagent and Biotin, within the Medical Devices & Diagnostics and Vitamins & Supplements categories. However, the lack of diversification in its product portfolio and limited market presence may hinder its ability to leverage unique strengths or competitive advantages.

3Strategic Position

Bionify Bioscience (opc) Private Limited's current strategic direction appears to be focused on a narrow product range, with a portfolio consisting solely of two products. This lack of diversification may limit the company's ability to adapt to changing market dynamics and regulatory environments. A broader strategic focus, including the development of new products and expansion into additional markets, could enhance the company's growth prospects and resilience.

Buyer Due Diligence Brief — Evaluating Bionify Bioscience (opc) Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

The company's export data indicates a total export value of $83,000 USD across 44 shipments, with a portfolio concentrated entirely on two products. This suggests a limited track record in terms of export volume and consistency. The reliance on a narrow product range may impact the company's reliability as a supplier, as it may not be able to meet diverse customer needs or adapt to varying market demands.

2Certifications to Verify

Importers considering engagement with Bionify Bioscience (opc) Private Limited should verify the following certifications:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practice standards, which is crucial for international trade.

Frequently Asked Questions — Bionify Bioscience (opc) Private Limited

How many pharmaceutical products does Bionify Bioscience (opc) Private Limited export from India?

Bionify Bioscience (opc) Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Reagent ($77.6K), Biotin ($4.9K). Total export value is $82.5K.

What is Bionify Bioscience (opc) Private Limited's total pharmaceutical export value?

Bionify Bioscience (opc) Private Limited's total pharmaceutical export value is $82.5K, based on 44 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bionify Bioscience (opc) Private Limited cover?

Bionify Bioscience (opc) Private Limited exports across 2 therapeutic categories. The largest are Medical Devices & Diagnostics (94.1%, 1 products), Vitamins & Supplements (5.9%, 1 products).

Get Full Bionify Bioscience (opc) Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.